Voyager Therapeutics (NASDAQ:VYGR) Receives Buy Rating from HC Wainwright

Voyager Therapeutics (NASDAQ:VYGR)‘s stock had its “buy” rating restated by investment analysts at HC Wainwright in a research report issued on Monday,Benzinga reports.

Other research analysts also recently issued research reports about the company. Wall Street Zen downgraded Voyager Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Weiss Ratings restated a “sell (d-)” rating on shares of Voyager Therapeutics in a research report on Monday, July 13th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $16.50.

Voyager Therapeutics Price Performance

Shares of VYGR opened at $3.27 on Monday. Voyager Therapeutics has a 52-week low of $2.93 and a 52-week high of $5.55. The company has a market capitalization of $197.57 million, a PE ratio of -1.82 and a beta of 1.31. The stock has a fifty day simple moving average of $3.40 and a two-hundred day simple moving average of $3.73.

Voyager Therapeutics (NASDAQ:VYGR) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.40) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.08. Voyager Therapeutics had a negative net margin of 312.63% and a negative return on equity of 54.82%. The business had revenue of $3.17 million during the quarter, compared to analysts’ expectations of $4.52 million. As a group, equities analysts anticipate that Voyager Therapeutics will post -1.43 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the business. Wexford Capital LP acquired a new stake in shares of Voyager Therapeutics in the third quarter valued at about $42,000. ProShare Advisors LLC purchased a new position in shares of Voyager Therapeutics in the fourth quarter valued at $44,000. CIBC Asset Management Inc acquired a new position in shares of Voyager Therapeutics during the 4th quarter worth $45,000. Coldstream Capital Management Inc. acquired a new position in shares of Voyager Therapeutics during the 3rd quarter worth $55,000. Finally, Caitong International Asset Management Co. Ltd boosted its position in shares of Voyager Therapeutics by 42,410.8% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 15,729 shares of the company’s stock worth $62,000 after buying an additional 15,692 shares in the last quarter. Hedge funds and other institutional investors own 48.03% of the company’s stock.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of gene therapies for serious neurological diseases. The company’s core activities center on the design and delivery of engineered adeno-associated viral (AAV) vectors tailored to target cells in the brain and central nervous system. Through its proprietary CapsidMap and VectorMap platforms, Voyager aims to enhance vector potency, specificity and durability to address diseases with high unmet medical need.

The firm’s pipeline includes several AAV-based candidates in preclinical and early clinical development.